Anixa Biosciences Stock Fundamentals
| ANIX Stock | USD 3.30 0.01 0.30% |
Anixa Biosciences fundamentals help investors to digest information that contributes to Anixa Biosciences' financial success or failures. It also enables traders to predict the movement of Anixa Stock. The fundamental analysis module provides a way to measure Anixa Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anixa Biosciences stock.
At this time, Anixa Biosciences' Interest Expense is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.2 M in 2024. Anixa | Select Account or Indicator |
Anixa Biosciences Company Shares Owned By Insiders Analysis
Anixa Biosciences' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Anixa Biosciences Shares Owned By Insiders | 5.05 % |
Most of Anixa Biosciences' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anixa Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 5.04599999999999% of Anixa Biosciences are shares owned by insiders. This is 66.76% lower than that of the Biotechnology sector and 64.41% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 49.99% higher than that of the company.
Anixa Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Anixa Biosciences's current stock value. Our valuation model uses many indicators to compare Anixa Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Anixa Biosciences competition to find correlations between indicators driving Anixa Biosciences's intrinsic value. More Info.Anixa Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Anixa Biosciences' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Anixa Biosciences' earnings, one of the primary drivers of an investment's value.Anixa Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anixa Biosciences' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Anixa Biosciences could also be used in its relative valuation, which is a method of valuing Anixa Biosciences by comparing valuation metrics of similar companies.Anixa Biosciences is currently under evaluation in shares owned by insiders category among its peers.
Anixa Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Anixa Biosciences from analyzing Anixa Biosciences' financial statements. These drivers represent accounts that assess Anixa Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Anixa Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 71.4M | 76.6M | 45.8M | 145.5M | 167.3M | 140.1M | |
| Enterprise Value | 68.3M | 73.1M | 39.4M | 116.6M | 134.1M | 134.2M |
Anixa Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Anixa Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Anixa Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Anixa Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 86.01 M | ||||
| Shares Outstanding | 32.18 M | ||||
| Shares Owned By Insiders | 5.05 % | ||||
| Shares Owned By Institutions | 17.40 % | ||||
| Number Of Shares Shorted | 411.56 K | ||||
| Price To Earning | (51.83) X | ||||
| Price To Book | 4.89 X | ||||
| Price To Sales | 481.54 X | ||||
| Revenue | 210 K | ||||
| Gross Profit | 127.5 K | ||||
| EBITDA | (10.96 M) | ||||
| Net Income | (9.93 M) | ||||
| Cash And Equivalents | 31.66 M | ||||
| Cash Per Share | 1.03 X | ||||
| Total Debt | 175 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.01 X | ||||
| Book Value Per Share | 0.68 X | ||||
| Cash Flow From Operations | (6.21 M) | ||||
| Short Ratio | 3.58 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Target Price | 8.5 | ||||
| Beta | 0.85 | ||||
| Market Capitalization | 106.19 M | ||||
| Total Asset | 25.52 M | ||||
| Retained Earnings | (228.2 M) | ||||
| Working Capital | 23.33 M | ||||
| Current Asset | 10.38 M | ||||
| Current Liabilities | 1.36 M | ||||
| Net Asset | 25.52 M |
About Anixa Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anixa Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anixa Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anixa Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.4 M | 1.3 M | |
| Total Revenue | 241.5 K | 229.4 K | |
| Cost Of Revenue | 185.2 K | 175.9 K | |
| Stock Based Compensation To Revenue | 18.95 | 19.90 | |
| Sales General And Administrative To Revenue | 26.96 | 28.31 | |
| Research And Ddevelopement To Revenue | 20.44 | 21.46 | |
| Capex To Revenue | 0.63 | 0.66 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (60.30) | (57.28) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.